Analyst Research

Report Title Price
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Jazz Pharmaceuticals PLC Narrows FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Raises Low End Of Prior FY 2013 EPS Guidance To A Range In Line With Analysts' Estimates


Tuesday, 5 Nov 2013 04:05pm EST 

Jazz Pharmaceuticals PLC announced that for fiscal 2013, it expects revenue to be in the range of $867-$877 million, GAAP net income per diluted share in the range of $3.63-$3.79 and adjusted net income per diluted share $6.30-$6.40. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $872 million and EPS of $6.30 for fiscal 2013. 

Company Quote

142.51
-0.81 -0.57%
25 Jul 2014